Program
Anti-CD37/DM1 Derivative Antibody-drug Conjugate Debio 1562M
Its studies are mostly in Leukemia, Myeloid, Acute, led by Debiopharm.
Furthest: phase 2, since May 5, 20251 company-led study, 1 open or runningNext primary completion: Nov 2031 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Debiopharm | 11 open or running | phase 2since May 5, 2025 | May 5, 2025 | Nov 2031phase 2 · NCT06969430 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 5, 2025First study: phase 2 study in Leukemia, Myeloid, AcuteFirst studyNCT06969430 · 154 planned · United States
Ahead
- Nov 2031Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT06969430
TargetBeta
CD37 →read by rule
“An antibody-drug conjugate (ADC) composed of naratuximab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) CD37, covalently ”NCIt, by rule
Other programs on CD37
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-CD37/DXd Antibody-drug Conjugate DS3790rule | Daiichi Sankyo | phase 2 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06969430Leukemia, Myeloid, Acute · United States | 2 | Recruiting | Nov 2031 | 154 |
How it is read
Names in the registry
- “Debio 1562M”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.